



#42000

**DATE: OCTOBER 13, 2017**

**SUBJECT: SCICLONE PHARMACEUTICALS, INC. – CASH  
SETTLEMENT/ACCELERATION OF EXPIRATIONS  
OPTION SYMBOL: SCLN  
DATE: 10/16/17**

On September 27, 2017, Shareholders of SciClone Pharmaceuticals, Inc. (SCLN) voted concerning the proposed merger with Silver Delaware Investment Limited, a subsidiary of Silver Biotech Investment Limited, both entities formed by a consortium of investors. The merger was approved and subsequently consummated on October 13, 2017. As a result, each existing SCLN Common Share will be converted into the right to receive \$11.18 net cash per share.

**CONTRACT ADJUSTMENT**

DATE: October 16, 2017

NEW DELIVERABLE  
PER CONTRACT: \$1,118.00 Cash (\$11.18 x 100)

Settlement in SCLN options will take place through OCC's cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable.

**ACCELERATION OF EXPIRATIONS**

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an acceleration of the expiration dates for outstanding option series. (See OCC Information Memo 23707) Additionally, the exercise by exception (ex by ex) threshold for expiring series will be \$.01 in all account types.

All series of SciClone Pharmaceuticals, Inc. options whose expiration dates are after 10-20-2017 will have their expiration dates advanced to 10-20-2017. Expiration dates occurring before 10-20-2017 (e.g., Flex options) will remain unchanged.

All SciClone Pharmaceuticals, Inc. options will utilize a \$.01 exercise threshold.

Option Symbol: SCLN  
Existing Expiration: All months  
New expiration date: 10-20-2017

Existing American-style SciClone Pharmaceuticals, Inc. options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue to settle in two business days.

**DISCLAIMER**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).